Half Yearly Report and Accounts

• Revenue decreased by 8% year-on-year to $1,428,421
• Net loss after tax increased to $2,012,559
• Significant progress in market entry and collaborations

Osteopore Ltd's half-yearly report for the period ended 30 June 2026 shows a revenue decrease of 8% to $1,428,421, compared to $1,558,847 in the previous corresponding period. The decrease was primarily due to the translation impact of a stronger Australian dollar against other currencies. Despite the revenue decline, the company saw growth in several markets including the Philippines, Vietnam, Japan, the United States, and Singapore, partially offset by lower sales in other regions. The net loss after tax increased to $2,012,559, reflecting higher expenses related to product development, sales, marketing, and business development. Despite the financial challenges, Osteopore made significant progress in market entry and collaborations, including an exclusive license with Accelerate Technologies and a multi-year collaboration with Majeton Pte Ltd.

Osteopore aims to continue expanding its product range and market presence, focusing on regulatory compliance and strategic collaborations.